G
Greg Yothers
Researcher at University of Pittsburgh
Publications - 190
Citations - 20700
Greg Yothers is an academic researcher from University of Pittsburgh. The author has contributed to research in topics: Colorectal cancer & Oxaliplatin. The author has an hindex of 56, co-authored 168 publications receiving 18158 citations. Previous affiliations of Greg Yothers include University of Florida & Yonsei University.
Papers
More filters
Journal ArticleDOI
Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer
Edward H. Romond,Edith A. Perez,John Bryant,Vera J. Suman,Charles E. Geyer,Nancy E. Davidson,Elizabeth Tan-Chiu,Silvana Martino,Soonmyung Paik,Peter A. Kaufman,Sandra M. Swain,Thomas M. Pisansky,Louis Fehrenbacher,Leila A. Kutteh,Victor G. Vogel,Daniel W. Visscher,Greg Yothers,Robert B. Jenkins,Ann M. Brown,S. R. Dakhil,Eleftherios P. Mamounas,Wilma L. Lingle,Pamela M. Klein,James N. Ingle,Norman Wolmark +24 more
TL;DR: Tastuzumab combined with paclitaxel after doxorubicin and cyclophosphamide improves outcomes among women with surgically removed HER2-positive breast cancer.
Journal ArticleDOI
Oxaliplatin Combined With Weekly Bolus Fluorouracil and Leucovorin As Surgical Adjuvant Chemotherapy for Stage II and III Colon Cancer: Results From NSABP C-07
J. Philip Kuebler,H. Samuel Wieand,Michael O’Connell,Roy E. Smith,Linda H. Colangelo,Greg Yothers,N. J. Petrelli,Michael Findlay,Thomas E. Seay,James N. Atkins,John L. Zapas,J. Wendall Goodwin,Louis Fehrenbacher,Ramesh K. Ramanathan,Barbara A. Conley,Patrick J. Flynn,Gamini S. Soori,Lauren K. Colman,Edward A. Levine,Keith S. Lanier,Norman Wolmark +20 more
TL;DR: The addition of oxaliplatin to weekly FULV significantly improved DFS in patients with stage II and III colon cancer, and FLOX can be recommended as an effective option in clinical practice.
Journal ArticleDOI
Preoperative Multimodality Therapy Improves Disease-Free Survival in Patients With Carcinoma of the Rectum: NSABP R-03
Mark S. Roh,Linda H. Colangelo,Michael J. O'Connell,Greg Yothers,Melvin Deutsch,Carmen J. Allegra,Morton S. Kahlenberg,Luis Baez-Diaz,Carol S. Ursiny,Nicholas J. Petrelli,Norman Wolmark +10 more
TL;DR: Preoperative chemoradiotherapy, compared with postoperative che MORADotherapy, significantly improved DFS and showed a trend toward improved OS.
Journal ArticleDOI
Assessment of Cardiac Dysfunction in a Randomized Trial Comparing Doxorubicin and Cyclophosphamide Followed by Paclitaxel, With or Without Trastuzumab As Adjuvant Therapy in Node-Positive, Human Epidermal Growth Factor Receptor 2-Overexpressing Breast Cancer: NSABP B-31
Elizabeth Tan-Chiu,Greg Yothers,Edward H. Romond,Charles E. Geyer,Michael S. Ewer,Deborah Keefe,Richard P. Shannon,Sandra M. Swain,Ann M. Brown,Louis Fehrenbacher,Victor G. Vogel,Thomas E. Seay,Priya Rastogi,Eleftherios P. Mamounas,Norman Wolmark,John Bryant +15 more
TL;DR: Administering trastuzumab with paclitaxel after AC increases incidence of congestive heart failure and lesser CD, and potential cardiotoxicity should be carefully considered when discussing benefits and risks of this therapy.
Journal ArticleDOI
Paclitaxel After Doxorubicin Plus Cyclophosphamide As Adjuvant Chemotherapy for Node-Positive Breast Cancer: Results From NSABP B-28
Eleftherios P. Mamounas,John Bryant,Barry C. Lembersky,Louis Fehrenbacher,Scot M. Sedlacek,Bernard Fisher,D. Lawrence Wickerham,Greg Yothers,Atilla Soran,Norman Wolmark +9 more
TL;DR: The addition of PTX to AC resulted insignificant improvement in DFS but no significant improvement in OS with acceptable toxicity, and toxicity with the AC --> PTX regimen was acceptable for the adjuvant setting.